Clinical TrialNov 3, 2026, 09:11 AM
Evaxion to Present Positive Phase 2 Data for Cancer Vaccine EVX-01 at SITC
AI Summary
Evaxion A/S announced it will present new biomarker data from its phase 2 trial of the personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The data includes analysis of systemic immunomodulatory effects when EVX-01 is combined with pembrolizumab. The phase 2 trial in advanced melanoma patients demonstrated a 75% Objective Response Rate (ORR), with responses sustained at three-year follow-up. The company's AI-Immunology™ platform was used to design the personalized vaccines.
Key Highlights
- Evaxion to present new biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at SITC 2026 Annual Meeting.
- Data includes analysis of broad systemic immunomodulatory effects of EVX-01 plus pembrolizumab.
- Phase 2 trial demonstrated an Objective Response Rate (ORR) of 75% in advanced melanoma patients.
- 12 out of 16 patients showed objective clinical responses, with four achieving complete response.
- Clinical and T-cell responses were sustained at three-year follow-up.
- 89% of EVX-01 neoantigen targets triggered a tumor-specific immune response.
Price Impact
More from EVAX